论文部分内容阅读
目的考察乳腺癌细胞系BICRH1中乳腺癌干细胞表面标志物CD44+CD24-的表达及其药物敏感性。方法流式细胞及荧光共聚焦显微镜考察BICRH1中CD44+CD24-表达情况,MTT法考察BICRH1对不同类型抗肿瘤药物敏感性。结果乳腺癌细胞系BICRH1表面CD44+CD24-表达比率在95%以上。MTT结果显示,5-氟尿嘧啶及顺铂在48h时对细胞生长无抑制作用,在72h时对细胞生长的IC50值均在50μmol.L-1以上;多柔比星在48h与72h时IC50值分别为3.4及1.3μmol.L-1;米托蒽醌在48h与72h时IC50值分别为4.7及2.6μmol.L-1;硼替佐米在48h与72h时IC50值均小于10nmol.L-1;曲妥珠单抗在48h与72h时对细胞生长均无抑制效应。结论 BICRH1是一株乳腺癌干细胞标志物CD44+CD24-高表达的细胞系,该细胞对抗代谢剂5-氟尿嘧啶、DNA交联剂顺铂及表皮生长因子受体Her-2靶向药物曲妥珠单抗均耐药,对蒽环类药物多柔比星及米托蒽醌中度敏感,对蛋白酶体抑制剂硼替佐米高度敏感,这些结果提示蒽环类可以用于乳腺癌干细胞的治疗,硼替佐米是乳腺癌干细胞靶向治疗中一个非常有潜力的药物。
Objective To investigate the expression of breast cancer stem cell surface marker CD44 + CD24- and its drug sensitivity in breast cancer cell line BICRH1. Methods The expression of CD44 + CD24- in BICRH1 was detected by flow cytometry and fluorescent confocal microscopy. The sensitivity of BICRH1 to different types of anti-tumor drugs was examined by MTT assay. Results The percentage of CD44 + CD24-positive cells in the breast cancer cell line BICRH1 was over 95%. The results of MTT showed that 5-Fluorouracil and cisplatin had no inhibitory effect on cell growth at 48h, and the IC50 value of cell growth was above 50μmol.L-1 at 72h. The IC50 values of doxorubicin at 48h and 72h IC50 of mitoxantrone at 48 and 72 h were 4.7 and 2.6 μmol·L-1, respectively; IC50 values of bortezomib at 48 and 72 h were all less than 10 nmol.L-1; Trastuzumab had no inhibitory effect on cell growth at 48h and 72h. Conclusions BICRH1 is a breast cancer stem cell marker CD44 + CD24-overexpressing cell line that is resistant to 5-fluorouracil, a metabolite of 5-fluorouracil, a cisplatin-based DNA crosslinker and a Her-2 targeted drug trastuzumab Mab were resistant to anthracycline, doxorubicin and mitoxantrone moderately sensitive to the proteasome inhibitor bortezomib highly sensitive, these results suggest that anthracycline can be used for the treatment of breast cancer stem cells, Bortezomib is a very potential drug in targeted therapy of breast cancer stem cells.